Hindawi Publishing Corporation
Experimental Diabetes Research
Volume 2011, Article ID 108328, 7 pages
theStreptozotocin-InducedType1 Diabetes Model
Yoko Ozawa,1,2Toshihide Kurihara,1,2Mariko Sasaki,1,2NorimitsuBan,1,2KenyaYuki,1,2
ShunsukeKubota,1,2and Kazuo Tsubota2
1Laboratory of Retinal Cell Biology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo 160-8582, Japan
2Department of Ophthalmology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo 160-8582, Japan
Correspondence should be addressed to Yoko Ozawa, email@example.com
Received 12 July 2011; Accepted 26 August 2011
Academic Editor: N. Cameron
Copyright © 2011 Yoko Ozawa et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Diabetic retinopathy, a vision-threatening disease, has been regarded as a vascular disorder. However, impaired oscillatory
potentials (OPs) in the electroretinogram (ERG) and visual dysfunction are recorded before severe vascular lesions appear. Here,
we review the molecular mechanisms underlying the retinal neural degeneration observed in the streptozotocin-(STZ-) induced
type 1 diabetes model. The renin-angiotensin system (RAS) and reactive oxygen species (ROS) both cause OP impairment and
reduced levels of synaptophysin, a synaptic vesicle protein for neurotransmitter release, most likely through excessive protein
degradation by the ubiquitin-proteasome system. ROS also decrease brain-derived neurotrophic factor (BDNF) and inner retinal
Therefore, suppressors of RAS or ROS, such as angiotensin II type 1 receptor blockers or the antioxidant lutein, respectively, are
potential candidates for neuroprotective and preventive therapies to improve the visual prognosis.
Diabetic retinopathy, a vision-threatening disease, has long
according to the proliferative status of the retinal vasculature
. The disorder involves hemorrhage, vascular obliteration,
and the resulting neovascularization; these events subse-
quently cause fibrovascular proliferation and then retinal
detachment, all of which can secondarily cause retinal neu-
ral degeneration. However, impaired visual function is re-
over, the atrophic appearance and dysfunction of the neural
retina continue to worsen clinically after the vascular lesions
become quiescent. Therefore, the diabetes-induced retinal
neural degeneration may progress independently of the vas-
On the other hand, current treatments for diabetic ret-
inopathy are mostly intended to regulate vascular changes
mediated by the action of vascular endothelial growth factor
(VEGF), by laser treatment to attenuate the hypoxic retinal
cells that produce VEGF, and by anti-VEGF drugs, as well
as blood glucose level. The future generation of therapies
is expected to target neural tissue and to elicit a better
visual prognosis. In the retina, a light stimulus activates
the phototransduction pathway in the photoreceptor cells
which span the outer layer of the retina, and is converted
into electric signals which are then processed through the
synaptic network system in the inner layer of the retina
to finally transmit the signals to the brain to form visual
function. This series of electric reactions in the retina can
be recorded as an electroretinogram (ERG), which is used
to evaluate retinal function objectively, both clinically in
humans and experimentally in animals [2, 3]. Diabetes-
related changes appear in the oscillatory potentials (OPs) in
the ERG of human patients; these changes represent inner
reported in the 1960s [2–4]. However, the molecular mech-
anisms underlying the diabetes-induced neural degeneration
and dysfunction of the retina are still not well understood,
and elucidating them is a current hot topic in the field of
2 Experimental Diabetes Research
diabetes research. In this paper, we review the molecular
mechanisms of neural degeneration revealed in the retina of
the streptozotocin-(STZ-) induced type 1 diabetes models.
Streptozotocin is a glucosamine-nitrosourea compound that
was originally identified as an antibiotic, but is also known
to have an anticancer effect. It is cytotoxic to pancreatic beta
cells after being transported through glucose transporter 2
model animals. Experimental diabetes can be induced in
both rats and mice by the intraperitoneal injection of STZ
[6–9]. In the mouse model, the blood glucose level reaches
over 500mg/dL after 1 month of diabetes, compared with
about 100–120mg/dL in control mice [6–9].
Although the above method is often used to make a
diabetes model, there do not appear to be pathological neo-
vascularization caused by vascular obliteration in these an-
imals, which is typical finding in severe diabetic patients.
However, this model shows apoptosis of the inner retinal
neurons, such as ganglion cells and amacrine cells, and the
can all contribute to the inner retinal dysfunction detected as
OP changes in the ERG. Interestingly, VEGF, which is found
at a high level in the diabetic retina [7, 12–15], is generally
protective for neurons. Thus, the current treatments, which
target the vascular impairments and VEGF, may not be
effective for the neural pathogenesis. To develop new treat-
ment approaches, it is therefore important to elucidate the
molecular mechanisms underlying the neurodegenerative
changes in diabetic retinopathy. For these studies, the STZ-
induced model is useful, because it mimics the diabetes-
induced OP change in the ERG observed in humans [6, 8,
In the following sections, we describe the molecular
mechanisms of neural degeneration in the retina of the STZ-
induced diabetes model, focusing on the renin-angiotensin
system (RAS) [6, 7, 18, 19] and oxidative stress [8, 20, 21].
3.The RAS inthe Neural Retinaof Diabetes
The RAS was originally recognized as a regulator of the sys-
temic blood pressure. One of its principal effectors, angi-
otensin II, was originally reported to be converted from a
precursor peptide, angiotensinogen, which is produced in
the liver and then sequentially converted into angiotensin II
by enzymes, renin in the kidney and angiotensin-converting
enzyme (ACE) in the lung, after it enters the circulation.
Angiotensin II promotes vessel contraction to elevate the
blood pressure, and this is known as systemic RAS. On
the other hand, recent studies have revealed that all the
RAS components can be generated within a given tissue
or organ. This is called tissue RAS and is found in the
heart, blood vessels, kidney, adrenal gland, pancreas, central
nervous system, reproductive system, and lymphatic and
adipose tissue , as well as the retina [23, 24]. Tissue RAS
can be regulated independently of the systemic RAS .
Angiotensin II has long been known to have a role in dia-
betic complications, such as nephropathy and retinopathy,
with evidence indicating that it affects the vascular system
of each organ or tissue [7, 18, 25] via tissue RAS, in a
paracrine fashion [25, 26]. Thus, the common mechanism
of these complications has been believed to be the effects of
angiotensin II on the vascular system [7, 18, 25]. However,
recent studies using the STZ-induced diabetes model have
begun to reveal the influences of angiotensin II on neural
cells [6, 27].
3.1. Influence of the RAS on Synapses. In STZ-induced dia-
betes model mice, angiotensin II and its type 1 receptor
(AT1R) are upregulated in the retina [6, 7]. Interestingly,
AT1R is abundantly coexpressed with synaptophysin, a syn-
aptic vesicle protein critical for neurotransmitter release, in
the inner layer of the normal mouse retina (Figure 1) ,
consistent with AT1R signaling role in modulating synaptic
activity in the central nervous system .
Kurihara et al. analyzed the role of AT1R in the diabetic
retina by administering the AT1R blockers telmisartan and
valsartan to STZ-induced diabetes model mice . AT1R
blockers suppressed the OP change in this model that
reflects impaired inner retinal function. Therefore, the visual
functional impairment in this STZ-induced diabetes model
reduced synaptophysin expression in a posttranscriptional
fashion in the retina of the diabetes model mice. This ob-
servation is consistent with the fact that the visual dysfunc-
tion in this model originates in the inner layer of the retina,
where the synaptic network system is located.
3.2. Direct Influence of the RAS on Neurons. The molecular
mechanism underlying the decrease in synaptophysin pro-
tein was analyzed using a neuronal cell line originated from a
pheochromocytoma, PC12D. In this cell line, AT1R is coex-
pressed with synaptophysin which is posttranscriptionally
decreased by adding angiotensin II to the culture medium
. This decrease is inhibited by both AT1R blockers and
AT1R knockdown using shRNA. Downstream of AT1R, ERK
is activated, which was also confirmed using inhibitors and
shRNA. This posttranscriptional reduction of synaptophysin
protein results from its excessive degradation through the
experiment showed that angiotensin II has a direct effect
on neuronal cells. ERK is activated in the diabetic retina
in vivo, suggesting that the same pathway is involved in
the neuronal pathogenesis in the retina of the STZ-induced
diabetes model. In another report on the effect of an ACE
inhibitor in these model animals, it was concluded that the
drug inhibited retinal degeneration by reducing the blood
pressure and blood glucose level . However, the in vivo
results of Kurihara et al. were obtained under conditions in
which the blood pressure and blood glucose levels did not
change, further supporting the idea that RAS has a direct
effect on neurons in vivo.
The role of angiotensin II in diabetic retinopathy has
tan Trials (DIRECTs) [31, 32], in which the effect of an
Experimental Diabetes Research3
Figure 1: Expression of angiotensin II type 1 receptor and syn-
aptophysin in the mouse retina. Expression of AT1R (green) in the
normal retina (A–C). The boxed area in A is magnified in B and C
(merged in C), and the boxed areas in C are magnified in the insets
of C. AT1R is coexpressed with synaptophysin (pink), a presynaptic
vesicle protein, in the IPL (arrow in the upper inset of C) and OPL
(arrows in B and the lower inset of C). AT1R, angiotensin II type 1
receptor; GCL, ganglion cell layer; IPL, inner plexiform layer; INL,
inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear
AT1R blocker on the incidence and progression of diabetic
Retinopathy Study (ETDRS) scale. Although this scale has
been established to evaluate vascular lesions of diabetic
retinopathy , the effect of the drug may also involve
improving the retinal neural condition taking into account
the data from the animal model .
3.3. RAS and UPS. Angiotensin II induces pathological UPS
activity in various tissues, including vascular smooth mus-
cle . Angiotensin II promotes the expression of atrogin-
1, an E3 ubiquitin ligase selective for skeletal muscle wast-
ing . Notably, another animal model of retinal tissue
inflammation, endotoxin-induced uveitis and retinitis, in
ges , shows the involvement of UPS-mediated exces-
sivedegradation ofrhodopsin, avisualsubstance,intheneu-
ronal dysfunction of the retina [36, 37]. Given that the
RAS contributes to various kinds of diabetic complications,
the UPS may have important roles in the diabetes-induced
pathogenesis, a possibility meriting further study.
the Neural Retinaof Diabetes
Oxidative stress is another key modulator of diabetic com-
plications [8, 20, 38]. Reactive oxygen species (ROS) can be
produced in mitochondria through the electron transport
chain [39, 40]. Keeping the levels of mitochondrial ROS
at normal levels by pharmacological method prevents the
activation of protein kinase C, the formation of advanced
glycation end products, sorbitol accumulation, and NF-κB
activation, all of which are coupled with diabetes-induced
vascular endothelial cell damage . In this section, we in-
troduce the mechanism of oxidative stress-induced neural
degeneration observed in the retina of the STZ-induced dia-
betes model .
4.1. Influence of Oxidative Stress on Synapses. The retinal
neuronal cells are influenced by ROS: in the STZ-induced
diabetes model mice, both the decrease in synaptophysin
protein and the ERG impairment are suppressed under the
constant administration of an antioxidant, lutein, which
suppresses the local ROS (Figure 2) and ERK activation in
the diabetic retina . This influence, shown by Sasaki et
al., is observed as early as 1 month from diabetic onset, the
same time as the RAS influence reported by Kurihara et al.
Since lutein also did not change the blood glucose level in
this analysis, but reduced the ROS level in the retina with
diabetes, the effect of lutein in the retina was, at least in part,
through the reduction of the diabetes-induced local ROS.
Another influence of ROS related to neuronal activity
is exerted on the expression of brain-derived neurotrophic
factor (BDNF). This factor regulates axonal growth and
synaptic activity as well as neuronal survival . The level
of BDNF in the diabetic retina is decreased [8, 42], but lutein
treatment prevents this reduction . The BDNF level is
regulated by neuronal synaptic activity , suggesting that
the mechanism of its preservation in the retina of diabetic
mice by lutein administration may involve the preservation
of synaptophysin protein and the subsequent protection of
neuronal synaptic activity.
In addition to promoting BDNF expression , synap-
tic activity promotes neuronal survival through depolar-
ization of the cell membrane and increasing the level of
intracellular calcium in the neuronal cells . Therefore,
the synaptic change observed in the diabetic retina affects,
at least in part, retinal neuronal survival and visual function.
Sasaki et al. showed that the thickness of the inner layer of
the retina, including the retinal ganglion cells and amacrine
cells, in the diabetes model mice is reduced 4 months
after diabetes onset , consistent with the previous report
showing similar changes in the model rats 7.5 months after
diabetes onset . However, in lutein-administered mice,
in which the synaptophysin and BDNF levels are preserved
after 1 month of diabetes, the thickness is preserved, and
the neuronal cells survive by constant treatment . Thus,
the antioxidative treatment by lutein appears to protect the
neuronal cells from apoptosis.
The antioxidant, lutein, is presently being studied for
its preventive effects on the progression of age-related
macular degeneration (AMD), a vision-threatening disease,
as a micronutrient supplement. It is a yellow pigment and
can filter blue light, which has a high energy level that is
toxic to the retina. However, interestingly, the preventive
effect of lutein observed in the retina of the STZ-induced
diabetes model occurs by the ROS reduction rather than
the filtering of light energy. Moreover, the fact that lutein is
physiologically delivered to the retinal neurons  suggests
that it might act directly in the retina, and not only as an
antioxidant. Further studies aimed at elucidating whether
lutein’s effects involve pathways other than the antioxidative
pathway should be performed.
4 Experimental Diabetes Research
Figure 2: Oxidative stress in the retina of the STZ-induced diabetes model mouse. Dihydroethidium (DHE) indicates ROS in the retina (a).
The level of diabetes-induced ROS in the retina is decreased by constant lutein treatment. Fluorescence intensity in the INL relative to that
of nondiabetic mice was measured by the Image J program (b). DHE, dihydroethidium; ROS, reactive oxygen species; GCL, ganglion cell
layer; IPL, inner plexiform layer; INL, inner nuclear layer (original copyright; , Figure 1, reproduced with the kind permission of Springer
Science + Business Media.)
4.2. Other Influences of Oxidative Stress in the Retina. The
influence of diabetes on neural retinal cells has also been
analyzed from other viewpoints. Under diabetic conditions,
the increase in superoxide anions in the neural retina leads to
a decreased bioavailability of nitric oxide which is originally
induced in the retina for tissue protection; the decrease in
nitric oxide action increases the formation of peroxynitrite,
factor, nerve growth factor (NGF), and neuronal survival
M¨ uller glial cells, which contribute to the homeostasis
of the retina, are also damaged by oxidative stress [47, 48].
These cells originate from a common retinal progenitor cell
the damage of these cells can also influence visual function.
The influences of oxidative stress on M¨ uller glial cells involve
the downregulation of a potassium channel, Kir4.1, a water
channel, aquaporin 4 , and matrix metalloproteinase-7
(MMP-7) which converts a toxic factor for neurons, pro-
nerve growth factor (pro-NGF), to a neuroprotective fac-
tor, NGF . Therefore, there are multiple pathways down-
stream of oxidative stress that can cause retinal neural cell
damage and decrease visual function.
Synaptophysin protein is decreased in the retina of the
STZ-induced diabetes model through both the AT1R-ERK
axis and the ROS-ERK axis, suggesting the involvement
of cross talk between angiotensin II and ROS signals in
the diabetic retina (Figure 3). Angiotensin II can activate
nicotinamide adenine dinucleotide phosphate (NAD(P)H)
oxidase via AT1R stimulation and produces ROS, as shown
in the pathogenesis of atherosclerosis [49–51]. Moreover,
angiotensin 1-7, which are cleaved from angiotensin II and
act as its negative regulators, are reduced in the retina with
diabetes , and their overexpression reduces diabetes-
induced oxidative stress in the retina, suggesting that their
reduction might also be related to the cross talk.
Indeed, the effect of angiotensin II on the retinal leu-
kostasis in diabetes occurs at least partly through NAD(P)H
Experimental Diabetes Research5
(a synaptic vesicle protein)
synaptic network activity
Visual function impairment
Figure 3: Model of retinal neural degeneration and visual im-
pairment in the STZ-induced diabetes model mouse. Cross-talk
between AT1R signaling and ROS is involved in the neural degen-
eration of the diabetic retina. Downstream of both these effectors,
ERK activation reduces synaptophysin, while ROS also decrease
BDNF. These changes impair visual function most probably
through synaptic network abnormalities and neuronal apoptosis.
AT1R, angiotensin II type 1 receptor; ROS, reactive oxygen species;
BDNF, brain-derived neurotrophic factor.
oxidase-related ROS generation, as shown using apocynin,
an antioxidant . The ROS generated downstream of
AT1R further upregulate multiple inflammatory cytokines,
such as TNF-α, IL1-β, and IFN-γ, which further induce ROS
. Collectively, these findings support the idea that RAS-
ROS cross talk has a large role in the pathogenesis of the
diabetes-induced degeneration of neural tissue.
Another outcome of the cross talk in the diabetic retina
may be the expression of VEGF. M¨ uller glial cells are the
responsible cells for VEGF induction in the diabetic retina,
and this induction is regulated by hypoxia-inducible factor-
1α (HIF-1α) , which can be activated by oxidative stress
. VEGF induction in the diabetic retina is also regulated
Further studies are required to assess the contribution of
the RAS-ROS interaction in the diabetic retinal degeneration
that leads to impaired visual function and its possibility as a
therapeutic target for this impairment.
Retinal neural cell loss is involved as one of the main causes
for visual deficits in diabetes, and given that the retinal neu-
ral tissue eventually regulates diabetes-induced vascular dis-
orders , it is essential to understand the molecular
mechanisms underlying the pathology in the retinal neural
cells to establish the next generation of therapies. To the best
antioxidants are the most promising candidates for future
neuronal cell survival and normalizing the microenviron-
ment, such as cytokine production in the neural tissue, in
the diabetic retina.
 J. Tang and T. S. Kern, “Inflammation in diabetic retinopathy,”
 J. Kizawa, S. Machida, T. Kobayashi, Y. Gotoh, and D.
Kurosaka, “Changes of oscillatory potentials and photopic
negative response in patients with early diabetic retinopathy,”
Japanese Journal of Ophthalmology, vol. 50, no. 4, pp. 367–373,
 D. Yonemura, T. Aoki, and K. Tsuzuki, “Electroretinogram in
diabetic retinopathy,” Archives of Ophthalmology, vol. 68, pp.
 W. Whitmire, M. M. Al-Gayyar, Y. Abdelsaid, B. K. Yousufzai,
and A. B. El-Remessy, “Alteration of growth factors and
neuronal death in diabetic retinopathy: what we have learned
so far,” Molecular Vision, vol. 17, pp. 300–308, 2011.
 W. J. Schnedl, S. Ferber, J. H. Johnson, and C. B. Newgard,
“STZ transport and cytotoxicity: specific enhancement in
GLUT2-expressing cells,” Diabetes, vol. 43, no. 11, pp. 1326–
 T. Kurihara, Y. Ozawa, N. Nagai et al., “Angiotensin II type
1 receptor signaling contributes to synaptophysin degradation
and neuronal dysfunction in the diabetic retina,” Diabetes, vol.
57, no. 8, pp. 2191–2198, 2008.
 N. Nagai, K. Izumi-Nagai, Y. Oike et al., “Suppression
of diabetes-induced retinal inflammation by blocking the
angiotensin II type 1 receptor or its downstream nuclear
factor-kappaB pathway,” Investigative Ophthalmology and
Visual Science, vol. 48, no. 9, pp. 4342–4350, 2007.
 M. Sasaki, Y. Ozawa, T. Kurihara et al., “Neurodegenerative
influence of oxidative stress in the retina of a murine model of
diabetes,” Diabetologia, vol. 53, no. 5, pp. 971–979, 2010.
 S. Satofuka, A. Ichihara, N. Nagai et al., “(Pro)renin receptor-
mediated signal transduction and tissue renin-angiotensin
system contribute to diabetes-induced retinal inflammation,”
Diabetes, vol. 58, no. 7, pp. 1625–1633, 2009.
 A. J. Barber, E. Lieth, S. A. Khin, D. A. Antonetti, A. G.
Buchanan, and T. W. Gardner, “Neural apoptosis in the retina
during experimental and human diabetes: early onset and
effect of insulin,” Journal of Clinical Investigation, vol. 102, no.
4, pp. 783–791, 1998.
glutamate metabolism in short-term experimental diabetic
retinopathy. Penn State Retina Research Group,” Diabetes, vol.
47, pp. 815–820, 1998.
 J. L. Wilkinson-Berka, “Vasoactive factors and diabetic ret-
inopathy: vascular endothelial growth factor, cycoloxygen-
no. 27, pp. 3331–3348, 2004.
6 Experimental Diabetes Research
 S. Ishida, T. Usui, K. Yamashiro et al., “VEGF164 is proinflam-
Visual Science, vol. 44, no. 5, pp. 2155–2162, 2003.
 S. Ishida, T. Usui, K. Yamashiro et al., “VEGF164-mediated
inflammation is required for pathological, but not physiolog-
ical, ischemia-induced retinal neovascularization,” Journal of
Experimental Medicine, vol. 198, no. 3, pp. 483–489, 2003.
 S. Ishida, K. Yamashiro, T. Usui et al., “Leukocytes mediate
retinal vascular remodeling during development and vaso-
 H. A. Hancock and T. W. Kraft, “Oscillatory potential
analysis and ERGs of normal and diabetic rats,” Investigative
Ophthalmology and Visual Science, vol. 45, no. 3, pp. 1002–
 K. Kohzaki, A. J. Vingrys, and B. V. Bui, “Early inner
retinal dysfunction in streptozotocin-induced diabetic rats,”
Investigative Ophthalmology & Visual Science, vol. 49, no. 8,
pp. 3595–3604, 2008.
 J. L. Wilkinson-Berka, “Diabetes and retinal vascular disor-
ders: role of the renin-angiotensin system,” Expert Reviews in
Molecular Medicine, vol. 6, no. 15, pp. 1–18, 2004.
 R. Bilous, N. Chaturvedi, A. K. Sjolie et al., “Effect of
candesartan on microalbuminuria and albumin excretion
rate in diabetes: three randomized trials,” Annals of Internal
Medicine, vol. 151, no. 1, pp. 11–20, 2009.
 P. Dandona, K. Thusu, S. Cook et al., “Oxidative damage to
DNA in diabetes mellitus,” The Lancet, vol. 347, no. 8999, pp.
 H. B. Lee, M. R. Yu, Y. Yang, Z. Jiang, and H. Ha, “Reac-
tive oxygen species-regulated signaling pathways in diabetic
nephropathy,” Journal of the American Society of Nephrology,
vol. 14, no. 3, pp. S241–S245, 2003.
 A. Ribeiro-Oliveira Jr., A. I. Nogueira, R. M. Pereira, W. W.
Vilas Boas, R. A. Dos Santos, and A. C. Simoes e Silva, “The
renin-angiotensin system and diabetes: an update,” Vascular
Health and Risk Management, vol. 4, no. 4, pp. 787–803, 2008.
 S. J. Sramek, I. H. L. Wallow, D. A. Tewksbury, C. R.
Brandt, and G. L. Poulsen, “An ocular renin-angiotensin
system: immunohistochemistry of angiotensinogen,” Inves-
tigative Ophthalmology & Visual Science, vol. 33, no. 5, pp.
 J. Wagner, A. H. J. Danser, F. H. M. Derkx et al.,
“Demonstration of renin mRNA, angiotensinogen mRNA,
and angiotensin converting enzyme mRNA expression in the
human eye: evidence for an intraocular renin-angiotensin
system,” British Journal of Ophthalmology, vol. 80, no. 2, pp.
 J. L. Wilkinson-Berka, “Angiotensin and diabetic retinopathy,”
International Journal of Biochemistry and Cell Biology, vol. 38,
no. 5-6, pp. 752–765, 2006.
 R. M. Carey and H. M. Siragy, “The intrarenal renin-
angiotensin system and diabetic nephropathy,” Trends in
Endocrinology and Metabolism, vol. 14, no. 6, pp. 274–281,
 E. L. Fletcher, J. A. Phipps, M. M. Ward, K. A. Vessey, and J.
L. Wilkinson-Berka, “The renin-angiotensin system in retinal
health and disease: its influence on neurons, glia and the
vasculature,” Progress in Retinal and Eye Research, vol. 29, no.
4, pp. 284–311, 2010.
 T. Kurihara, Y. Ozawa, K. Shinoda et al., “Neuroprotective
effects of angiotensin II type 1 receptor (AT1R) blocker,
telmisartan, via modulating AT1R and AT2R signaling in
retinal inflammation,” Investigative Ophthalmology & Visual
Science, vol. 47, no. 12, pp. 5545–5552, 2006.
 D. P. Li, S. R. Chen, and H. L. Pan, “Angiotensin II stimulates
spinally projecting paraventricular neurons through presy-
naptic disinhibition,” Journal of Neuroscience, vol. 23, no. 12,
pp. 5041–5049, 2003.
 B. V. Bui, J. A. Armitage, M. Tolcos, M. E. Cooper, and A.
J. Vingrys, “ACE inhibition salvages the visual loss caused by
diabetes,” Diabetologia, vol. 46, no. 3, pp. 401–408, 2003.
 N. Chaturvedi, M. Porta, R. Klein et al., “Effect of can-
desartan on prevention (DIRECT-Prevent 1) and progression
(DIRECT-Protect 1) of retinopathy in type 1 diabetes: ran-
domised, placebo-controlled trials,” The Lancet, vol. 372, no.
9647, pp. 1394–1402, 2008.
 A. K. Sjolie, R. Klein, M. Porta et al., “Effect of candesartan on
progression and regression of retinopathy in type 2 diabetes
(DIRECT-Protect 2): a randomised placebo-controlled trial,”
The Lancet, vol. 372, no. 9647, pp. 1385–1393, 2008.
 “Grading diabetic retinopathy from stereoscopic color fundus
photographs—an extension of the modified Airlie house
classification. ETDRS report number 10. Early Treatment
Diabetic Retinopathy Study Research Group,” Ophthalmology,
vol. 98, pp. 786–806, 1991.
 D. M. Zhang, T. He, Z. S. Katusic, H. C. Lee, and T. Lu,
“Muscle-specific F-Box only proteins facilitate BK channel
beta(1) subunit downregulation in vascular smooth muscle
cells of diabetes mellitus,” Circulation Research, vol. 107, no.
12, pp. 1454–1459, 2010.
 T. Yoshida, L. Semprun-Prieto, S. Sukhanov, and P. Dela-
fontaine, “IGF-1 prevents ANG II-induced skeletal muscle
atrophy via Akt- and Foxo-dependent inhibition of the
ubiquitin ligase atrogin-1 expression,” American Journal of
Physiology, vol. 298, no. 5, pp. H1565–H1570, 2010.
 Y. Ozawa, T. Kurihara, K. Tsubota, and H. Okano, “Regulation
of posttranscriptional modification as a possible therapeutic
approach for retinal neuroprotection,” Journal of Ophthalmol-
ogy, vol. 2011, Article ID 506137, 2011.
pathway in regulating the visual function and ubiquitin-
proteasome-dependent degradation of rhodopsin during reti-
nal inflammation,” Journal of Biological Chemistry, vol. 283,
no. 36, pp. 24561–24570, 2008.
 R. A. Kowluru and P. S. Chan, “Oxidative stress and diabetic
retinopathy,” Experimental Diabesity Research, vol. 2007, Arti-
cle ID 43603, 2007.
 J. W. Russell, D. Golovoy, A. M. Vincent et al., “High glucose-
induced oxidative stress and mitochondrial dysfunction in
nuerons,” FASEB Journal, vol. 16, no. 13, pp. 1738–1748, 2002.
 T. Nishikawa, D. Edelstein, X. L. Du et al., “Normalizing
mitochondrial superoxide production blocks three pathways
of hyperglycaemic damage,” Nature, vol. 404, no. 6779, pp.
 C. Cunha, R. Brambilla, and K. L. Thomas, “A simple role
for BDNF in learning and memory?” Frontiers in Molecular
Neuroscience, vol. 3, article 1, 2010.
 M. Seki, T. Tanaka, H. Nawa et al., “Involvement of brain-
derived neurotrophic factor in early retinal neuropathy of
streptozotocin-induced diabetes in rats: therapeutic poten-
tial of brain-derived neurotrophic factor for dopaminergic
amacrine cells,” Diabetes, vol. 53, no. 9, pp. 2412–2419, 2004.
 K. Kohara, A. Kitamura, M. Morishima, and T. Tsumoto,
“Activity-dependent transfer of brain-derived neurotrophic
Experimental Diabetes Research7 Download full-text
 K. Ikegami and T. Koike, “Membrane depolarization-
mediated survival of sympathetic neurons occurs through
both phosphatidylinositol 3-kinase- and CaM kinase II-
dependent pathways,” Brain Research, vol. 866, no. 1-2, pp.
 P. Bhosale, B. Li, M. Sharifzadeh et al., “Purification and
partial characterization of a lutein-binding protein from
human retina,” Biochemistry, vol. 48, no. 22, pp. 4798–4807,
 T. K. Ali, S. Matragoon, B. A. Pillai, G. I. Liou, and A. B. El-
Remessy, “Peroxynitrite mediates retinal neurodegeneration
by inhibiting nerve growth factor survival signaling in experi-
mental and human diabetes,” Diabetes, vol. 57, no. 4, pp. 889–
 T. K. Ali, M. M. Al-Gayyar, S. Matragoon et al., “Diabetes-
factor and nerve growth factor, and causes neurovascular
injury,” Diabetologia, vol. 54, pp. 657–668, 2010.
 T. M. Curtis, R. Hamilton, P. H. Yong et al., “Muller glial
dysfunction during diabetic retinopathy in rats is linked
to accumulation of advanced glycation end-products and
advanced lipoxidation end-products,” Diabetologia, vol. 54,
pp. 690–698, 2010.
 K. K. Griendling, C. A. Minieri, J. D. Ollerenshaw, and R.
W. Alexander, “Angiotensin II stimulates NADH and NADPH
oxidase activity in cultured vascular smooth muscle cells,”
Circulation Research, vol. 74, no. 6, pp. 1141–1148, 1994.
 V. J. Dzau, “Theodore Cooper lecture: tissue angiotensin
and pathobiology of vascular disease: a unifying hypothesis,”
Hypertension, vol. 37, pp. 1047–1052, 2001.
 M. Sata and D. Fukuda, “Crucial role of renin-angiotensin
system in the pathogenesis of atherosclerosis,” Journal of
Medical Investigation, vol. 57, no. 1-2, pp. 12–25, 2010.
 A. Verma, Z. Shan, B. Lei et al., “ACE2 and Ang-(1–7) con-
fer protection against development of diabetic retinopathy,”
Molecular Therapy. In press.
 P. Chen, A. M. Guo, P. A. Edwards, G. Trick, and A. G. Scicli,
“Role of NADPH oxidase and ANG II in diabetes-induced
retinal leukostasis,” American Journal of Physiology, vol. 293,
no. 4, pp. R1619–R1629, 2007.
 M. Lin M, Y, J, Y. Chen, J. Jin et al., “Ischaemia-induced
retinal neovascularisation and diabetic retinopathy in mice
with conditional knockout of hypoxia-inducible factor-1 in
retinal Muller cells,” Diabetologia, vol. 54, no. 6, pp. 1554–
 S. Reuter, S. C. Gupta, M. M. Chaturvedi, and B. B. Aggarwal,
“Oxidative stress, inflammation, and cancer: how are they
linked?” Free Radical Biology & Medicine, vol. 49, no. 11, pp.